Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing adeno-associated virus (AAV)-based treatments for severe neurological diseases. The company's pipeline targets Parkinson's disease, Alzheimer's disease, and other CNS disorders, with lead programs in mid-to-late stage clinical development. Revenue has contracted sharply (-68% YoY) as collaboration milestone payments have declined, while the company burns approximately $30M annually in operating cash.
Voyager operates a typical pre-commercial biotech model: monetizing intellectual property through upfront licensing fees, research milestone payments, and future royalties on partnered programs. The company's TRACER AAV capsid technology platform provides differentiation by enabling enhanced CNS tissue penetration and reduced immunogenicity. With 100% gross margins on collaboration revenue but -104% operating margins, the business is entirely dependent on advancing clinical programs to trigger milestone payments or achieving regulatory approval for proprietary assets. Pricing power will emerge only upon commercial launch, where gene therapies typically command $500K-$2M+ per patient treatment.
Clinical trial data readouts for lead Parkinson's and Alzheimer's programs (efficacy, safety, biomarker responses)
FDA regulatory milestones including IND clearances, Fast Track designations, and BLA submissions
New pharma partnership announcements with upfront payments or expanded collaboration terms
Cash runway updates and equity financing announcements (dilution concerns with 6.19x current ratio suggesting 18-24 months runway)
Competitive gene therapy trial results from Neurocrine, Sangamo, or other AAV-based CNS programs
AAV gene therapy immunogenicity concerns and potential for adverse regulatory actions following industry-wide safety signals (hepatotoxicity, thrombotic microangiopathy observed in competing programs)
Medicare/Medicaid reimbursement uncertainty for ultra-high-cost gene therapies ($1M+ per treatment) as payers implement outcomes-based contracts and amortization requirements
Manufacturing scalability challenges for AAV vectors at commercial scale, with limited CDMO capacity industry-wide
Well-capitalized competitors (Neurocrine, Sangamo, Spark Therapeutics) advancing parallel AAV-CNS programs with potentially superior capsid designs or earlier clinical timelines
Alternative modalities including antisense oligonucleotides (ASOs), small molecules, and antibody therapies targeting same neurological indications with lower manufacturing complexity
Patent expiration risks on foundational AAV technology (2030s) and freedom-to-operate challenges in crowded gene therapy IP landscape
Accelerating cash burn with no near-term revenue catalysts creates equity dilution risk within 12-18 months at current $30M annual OpEx run rate
Dependence on volatile collaboration revenue (down 68% YoY) creates unpredictable cash flow timing and potential covenant violations if debt is raised
Negative tangible book value (-48.9% ROE) limits asset-backed financing options and increases cost of capital
low - Pre-revenue biotechnology companies are largely insulated from GDP fluctuations as they generate no product sales and R&D spending is driven by clinical milestones rather than economic conditions. However, severe recessions can impact pharma partners' willingness to initiate new collaborations or advance existing programs.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (gene therapy revenues unlikely before 2028+). Higher rates also increase opportunity cost of capital for speculative biotech investments, driving rotation toward profitable growth or value stocks. Financing costs remain minimal given low debt levels (0.17x D/E), but equity raises become more dilutive as share prices compress.
minimal - The company maintains strong liquidity (6.19x current ratio) and minimal debt, eliminating near-term refinancing risk. Credit market conditions affect ability to secure non-dilutive financing (venture debt, royalty monetizations), but equity markets remain primary capital source for clinical-stage biotechs.
growth - Attracts speculative biotech investors focused on binary clinical catalysts and potential multi-bagger returns from successful gene therapy approvals. The -20.9% one-year return and -68% revenue decline indicate current shareholder base is concentrated in risk-tolerant funds willing to hold through clinical development volatility. Not suitable for income or value investors given negative profitability, no dividends, and 0.9x P/B suggesting market skepticism about asset realization.
high - Clinical-stage biotechnology stocks exhibit extreme volatility around binary events (trial readouts, FDA decisions). The -17% three-month return demonstrates sensitivity to sector rotation and risk-off sentiment. Expect 30-50% single-day moves on material clinical data releases, with beta likely exceeding 1.5x relative to broader biotech indices.
